Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$162.42 - $220.56 $1,624 - $2,205
-10 Reduced 0.7%
1,415 $239,000
Q3 2022

Nov 14, 2022

BUY
$160.42 - $256.21 $228,598 - $365,099
1,425 New
1,425 $267,000
Q1 2022

May 16, 2022

SELL
$161.19 - $257.96 $203,099 - $325,029
-1,260 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$247.59 - $304.47 $6,437 - $7,916
26 Added 2.11%
1,260 $334,000
Q3 2021

Nov 15, 2021

SELL
$194.77 - $324.21 $93,879 - $156,269
-482 Reduced 28.09%
1,234 $357,000
Q1 2021

May 07, 2021

BUY
$180.37 - $226.26 $309,514 - $388,262
1,716 New
1,716 $334,000
Q3 2018

Oct 25, 2018

SELL
$46.8 - $58.97 $596,372 - $751,454
-12,743 Closed
0 $0
Q2 2018

Aug 02, 2018

BUY
$35.26 - $47.04 $449,318 - $599,430
12,743 New
12,743 $599,000
Q2 2018

Jul 25, 2018

SELL
$35.26 - $47.04 $470,474 - $627,654
-13,343 Closed
0 $0
Q1 2018

May 01, 2018

BUY
$30.92 - $37.27 $412,565 - $497,293
13,343 New
13,343 $483,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.02B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.